Satellos Bioscience continues private Satellos Bioscience through amalgamation with iCo Therapeutics, carrying forward research into muscle stem cell regulation and regeneration. The company develops oral small molecule therapies designed to restore the body's natural muscle repair process. Its lead program forazapadin targets AAK1 to re-establish asymmetric stem cell division in Duchenne muscular dystrophy and facioscapulohumeral muscular dystrophy.
Satellos focuses on repair biology rather than replacing defective genes, using a dystrophin-independent oral approach that can stand alone or complement other therapies. Differentiation rests on small molecule AAK1 inhibition, muscle regeneration mechanism, and breadth across Duchenne and facioscapulohumeral indications. It serves people living with degenerative muscle diseases seeking treatments that improve muscle repair and function.